A new type of vaccine that can be stored at warmer temperatures, removing the need for refrigeration, has been developed for mosquito-borne virus Chikungunya in a major advance in vaccine technology.
The findings, published in Science Advances today [Wednesday 25 September], reveal exceptionally promising results for the Chikungunya vaccine candidate, which has been engineered using a synthetic protein scaffold that could revolutionise the way vaccines are designed, produced and stored.
Infectious diseases continue to plague populations worldwide. Among the means at our disposal to counter this threat, vaccination has proven to be exceptionally powerful. Smallpox has been eradicated, measles, polio and tetanus constrained from the world by vaccination. However, severe challenges to human health persist, evidenced by epidemics caused by Ebola, Zika and others. This is particularly severe in developing countries which often lack adequate infrastructure and resources to prevent or manage outbreaks, bringing about disruption and damage in affected communities and massive economic shortfall.
A recent example is Chikungunya, a virus transmitted by the bite of an infected mosquito. The disease causes crippling headache, vomiting, swelling of limbs and can lead to death. Even if a fever ends abruptly, chronic symptoms such as intense joint pain, insomnia and extreme prostration remain. Formerly confined to sub-Saharan Africa, Chikungunya has recently spread worldwide as its mosquito host leaves its natural habitat due to deforestation and climate change, with recent outbreaks in USA and Europe causing alarm.
Researchers from the University of Bristol and the French National Centre for Scientific Research (CNRS) in Grenoble, France, teamed up with computer technology giant Oracle to find a way to make vaccines that are thermostable (able to withstand warm temperatures), can be designed quickly and are easily produced.
“We were working with a protein that forms a multimeric particle resembling a virus but is completely safe, because it has no genetic material inside, said Pascal Fender, expert virologist at CNRS. “Completely by chance, we discovered that this particle was incredibly stable even after months, without refrigeration.”
“This particle has a very flexible, exposed surface that can be easily engineered, added Imre Berger, Director of the Max Planck-Bristol Centre for Minimal Biology in Bristol. “We figured that we could insert small, harmless bits of Chikungunya to generate a virus-like mimic we could potentially use as a vaccine.”
To validate their design, the scientists employed cryo-electron microscopy, a powerful new technique recently installed in Bristol’s state-of-the-art microscopy facility headed by Christiane Schaffitzel, co-author of the study. Cryo-EM yields very large data sets from which the structure of a sample can be determined at near atomic resolution, requiring massive parallel computing.
Enabled by Oracle’s high-performance cloud infrastructure, the team developed a novel computational approach to create an accurate digital model of the synthetic vaccine. University of Bristol IT specialists Christopher Woods and Matt Williams, together with colleagues at Oracle, implemented software packages seamlessly on the cloud in this pioneering effort. Christopher explained: “We were able to process the large data sets obtained by the microscope on the cloud in a fraction of the time and at much lower cost than previously thought possible.”
“Researchers have had a long tradition of building and installing their own super computers on-premises, but cloud computing is allowing them to run large data sets in record time, with fast connectivity and low latency. This is helping them crunch data and make scientific breakthroughs much faster. Going forward, technologies like machine learning and cloud computing will play a significant part in the scientific world, and we are delighted we could help the researchers with this important discovery,” added Phil Bates, leading cloud architect at Oracle.
The particles the scientists designed yielded exceptionally promising results in animal studies, soundly setting the stage for a future vaccine to combat Chikungunya disease.
“We were thoroughly delighted,” continued Imre Berger. “Viruses are waiting to strike, and we need to have the tools ready to tackle this global threat. Our vaccine candidate is easy to manufacture, extremely stable and elicits a powerful immune response. It can be stored and transported without refrigeration to countries and patients where it is most needed. Intriguingly, we can now rapidly engineer similar vaccines to combat many other infectious diseases just as well.”
“It really ticks a lot of boxes,” concluded Fred Garzoni, founder of Imophoron Ltd, a Bristol biotech start-up developing new vaccines derived from the present work. “Many challenges in the industry require innovative solutions, to bring powerful new vaccines to patients. Matching cutting-edge synthetic biology with cloud computing turned out to be a winner.”
The Latest on: Synthetic vaccines
via Google News
The Latest on: Synthetic vaccines
- Local Bio-Corridor entities monitoring coronavirus caseson January 24, 2020 at 4:43 pm
And being able to make either vaccine products that companies come up with or monoclonal antibodies that can be used to treat as a synthetic immune response to the virus," said Steven Pincus, the head ...
- Two local labs working on developing coronavirus vaccineon January 24, 2020 at 3:23 pm
"Its a big difference, like an electric car versus a model T," says Kim. He says traditional ways to make vaccine use the actual virus, but researchers here take just the genetic code, using a ...
- How fast can biotech come up with a vaccine for the latest outbreak?on January 24, 2020 at 1:08 pm
Moderna, which has already run clinical trials on six vaccines of its own, believes it’s up to the task. The company’s technology involves creating synthetic messenger RNA that can compel the body to ...
- Saskatchewan lab joins global effort to develop coronavirus vaccineon January 24, 2020 at 1:04 am
SASKATOON — As Canadian public health agencies prepare to deal with a new viral illness, a specialized lab in Saskatoon is using its research on different strains of the coronavirus to help develop a ...
- Saskatoon lab joins global effort to develop coronavirus vaccineon January 23, 2020 at 11:09 pm
His lab is now using it to hopefully find a way to help. The lab also has clearance to handle samples of the pathogen and is attempting to get samples from China or the U.S. If that’s not possible, it ...
- Researchers at Rush University Medical Center Find That Injecting Influenza Vaccines Into Tumors Triggers Immune System Responseon January 23, 2020 at 1:00 pm
/PRNewswire/ -- Changing the microenvironment of tumors to increase the immune system's response to them has been the goal of countless research and ...
- Vaccines & Vaccination Market 2018-2028 Registering CAGR of 10.5% and Generating Revenue USD 769.4 Millionon January 23, 2020 at 4:22 am
The global vaccines & vaccination market is expected to grow at the CAGR of 10.5% during 2018-2028. The market has generated revenue of more than $ 467 million in 2018 and is projected to reach up to ...
- 'Soft' robotic heart that uses synthetic material could put an end to human transplants by 2028on January 22, 2020 at 4:00 pm
As well as the robotic heart, the shortlisted projects include a vaccine for heart disease ... The 'hybrid heart' project - led by the University of Amsterdam - uses synthetic robotic material that ...
- Inputs of Macromolecular Engineering in the Design of Injectable Hydrogels Based on Synthetic Thermoresponsive Polymerson January 16, 2020 at 6:48 am
His current research focuses on the synthesis of polymer biomaterials for vaccine/drug delivery ... Injectable hydrogels can be made from natural and synthetic polymers. Originally, natural polymers ...
- Tangential Flow Filtration Market Study, 2019-2024 - Viral Vector & Vaccine Purification Applications to Witness Lucrative Growthon January 15, 2020 at 12:30 pm
The microfiltration segment is expected to be the fastest-growing due to its efficacy in removing natural and synthetic organic matter to reduce fouling potential. Viral vector and vaccine ...
via Bing News